Gene S-phase kinase associated protein 2 is a novel prognostic marker in human neoplasms.
Biomarker
Cancer biology
Expression
Immunology
Prognosis
Journal
BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628
Informations de publication
Date de publication:
12 06 2023
12 06 2023
Historique:
received:
12
06
2022
accepted:
29
05
2023
medline:
14
6
2023
pubmed:
13
6
2023
entrez:
12
6
2023
Statut:
epublish
Résumé
Neoplasms are a series of diseases affecting human health. Prognostic and tumor status-related markers for various tumors should be identified. Based on 19,515 samples from multiple sources, for the first time, this study provided an overview of gene S-phase kinase associated protein 2 (SKP2) in pan-cancer. Differential SKP2 expression in multiple comparison groups was identified by the Kruskal-Wallis test and Wilcoxon rank-sum test. The prognosis significance of SKP2 in individuals with neoplasm was evaluated through univariate Cox regression analysis and Kaplan-Meier curves. The area under the curve was utilized to detect the accuracy of SKP2 in predicting cancer status. Spearman's rank correlation coefficients were calculated in all correlation analyses. Gene set enrichment analysis was used to identify essential signaling pathways of SKP2 in human neoplasms. The study disclosed the upregulated SKP2 expression in 15 neoplasms and decreased SKP2 expression in three cancers (p < 0.05). The transcription factor Forkhead Box M1 may contribute to the increased expression levels of SKP2 in certain tumors. Over-expressed SKP2 represented a risk factor for the prognosis of most cancer patients (hazard ratio > 1, p < 0.05). SKP2 expression made it feasible to distinguish neoplasm and control tissues of 21 neoplasms (sensitivity = 0.79, specificity = 0.87, area under the curve = 0.90), implying its potential in screening a series of neoplasms. Further, the research revealed the close association of SKP2 expression with DNA methyltransferases, mismatch repair genes, microsatellite instability, tumor mutational burden, neoantigen count, and immunity. SKP2 plays an essential role in multiple neoplasms and may serve as a marker for treating and identifying these neoplasms.
Sections du résumé
BACKGROUND
Neoplasms are a series of diseases affecting human health. Prognostic and tumor status-related markers for various tumors should be identified.
METHODS
Based on 19,515 samples from multiple sources, for the first time, this study provided an overview of gene S-phase kinase associated protein 2 (SKP2) in pan-cancer. Differential SKP2 expression in multiple comparison groups was identified by the Kruskal-Wallis test and Wilcoxon rank-sum test. The prognosis significance of SKP2 in individuals with neoplasm was evaluated through univariate Cox regression analysis and Kaplan-Meier curves. The area under the curve was utilized to detect the accuracy of SKP2 in predicting cancer status. Spearman's rank correlation coefficients were calculated in all correlation analyses. Gene set enrichment analysis was used to identify essential signaling pathways of SKP2 in human neoplasms.
RESULTS
The study disclosed the upregulated SKP2 expression in 15 neoplasms and decreased SKP2 expression in three cancers (p < 0.05). The transcription factor Forkhead Box M1 may contribute to the increased expression levels of SKP2 in certain tumors. Over-expressed SKP2 represented a risk factor for the prognosis of most cancer patients (hazard ratio > 1, p < 0.05). SKP2 expression made it feasible to distinguish neoplasm and control tissues of 21 neoplasms (sensitivity = 0.79, specificity = 0.87, area under the curve = 0.90), implying its potential in screening a series of neoplasms. Further, the research revealed the close association of SKP2 expression with DNA methyltransferases, mismatch repair genes, microsatellite instability, tumor mutational burden, neoantigen count, and immunity.
CONCLUSIONS
SKP2 plays an essential role in multiple neoplasms and may serve as a marker for treating and identifying these neoplasms.
Identifiants
pubmed: 37308972
doi: 10.1186/s12920-023-01561-4
pii: 10.1186/s12920-023-01561-4
pmc: PMC10259050
doi:
Substances chimiques
S-Phase Kinase-Associated Proteins
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
128Informations de copyright
© 2023. The Author(s).
Références
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Clin Cancer Res. 2015 Sep 1;21(17):3841-52
pubmed: 26048278
Fam Cancer. 2017 Oct;16(4):525-529
pubmed: 28405781
Mol Cancer Ther. 2022 Jul 5;21(7):1184-1194
pubmed: 35499393
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Breast Cancer (Auckl). 2015 Aug 04;9(Suppl 1):13-21
pubmed: 26309408
Nat Commun. 2023 Jan 13;14(1):201
pubmed: 36639369
Clin Chem. 2019 Oct;65(10):1228-1238
pubmed: 31315901
Nat Rev Cancer. 2017 Apr;17(4):209-222
pubmed: 28233802
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Urol Oncol. 2011 May-Jun;29(3):302-8
pubmed: 19450994
BMC Bioinformatics. 2019 Sep 9;20(1):463
pubmed: 31500569
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
J BUON. 2017 Sep-Oct;22(5):1122-1130
pubmed: 29135092
Annu Rev Immunol. 2019 Apr 26;37:173-200
pubmed: 30550719
Nucleic Acids Res. 2023 Jan 6;51(D1):D587-D592
pubmed: 36300620
Cancer Cell Int. 2020 Jan 13;20:16
pubmed: 31956294
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Eur J Haematol. 2007 Jun;78(6):457-67
pubmed: 17391336
Cancer Cell. 2021 Feb 8;39(2):154-173
pubmed: 33125859
Cell Cycle. 2016 May 18;15(10):1344-51
pubmed: 27111245
Oncogene. 2020 Sep;39(39):6218-6230
pubmed: 32826949
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Pathol Oncol Res. 2016 Jul;22(3):625-32
pubmed: 26874697
BMB Rep. 2022 Feb;55(2):72-80
pubmed: 35168702
Br J Cancer. 2022 Oct;127(6):969-975
pubmed: 35752713
Am J Pathol. 2002 Jul;161(1):207-16
pubmed: 12107105
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Nat Rev Dis Primers. 2021 Jan 14;7(1):3
pubmed: 33446664
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
Immunity. 2016 Mar 15;44(3):698-711
pubmed: 26982367
Semin Cancer Biol. 2020 Dec;67(Pt 2):16-33
pubmed: 32014608
Chin J Cancer Res. 2021 Dec 31;33(6):637-648
pubmed: 35125808
Mol Oncol. 2022 Aug;16(15):2771-2787
pubmed: 35673965
Am J Pathol. 2004 Jul;165(1):175-80
pubmed: 15215173
Mutat Res Rev Mutat Res. 2019 Apr - Jun;780:15-28
pubmed: 31395346
Clin Cancer Res. 2008 Feb 1;14(3):685-91
pubmed: 18245527
Cancer Sci. 2004 Dec;95(12):969-76
pubmed: 15596046
Biomark Insights. 2019 May 08;14:1177271919846454
pubmed: 31105426
Nucleic Acids Res. 2019 Jan 8;47(D1):D729-D735
pubmed: 30462313
Medicine (Baltimore). 2021 Aug 20;100(33):e26951
pubmed: 34414959
Protein Sci. 2019 Nov;28(11):1947-1951
pubmed: 31441146
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
CA Cancer J Clin. 2022 Sep;72(5):409-436
pubmed: 35736631
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
J Exp Clin Cancer Res. 2019 Feb 13;38(1):76
pubmed: 30760284
Cells. 2021 Jun 12;10(6):
pubmed: 34204736
Oncol Lett. 2020 Sep;20(3):2788-2796
pubmed: 32782596
Sci Rep. 2018 Sep 24;8(1):14294
pubmed: 30250282
Cancer Sci. 2005 Oct;96(10):676-83
pubmed: 16232199